Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

Click for more information

0.00%

$1.75 viralytics limited

Thanks

First 9 Last

Share
Profile

Follow
The other one

553 Posts.

31/10/17

16:49

Post #: 28361211
Share

Originally posted by DavieJones ↑

My understanding is that Keytruda achieves an ORR (Objective Response Rate) of ~15% as a monotherapy in NSCLC, which is not much better than chemo in a first-line therapy (hence Merck's lack of enthusiasm in applying for EU approval). The most promising results so far are from the combination of Incytes' IDO inhibitor with Keytuda in a Phase 1 trial in NSCLC, which achieved ~30% ORR (but with small patient numbers at this stage).

If the Cavatak/Keytruda trial generates equivalent or better results in NSCLC, then Merck will be extremely interested. Ultimately, Merck wants the best combination treatment with Keytruda to be approved as the first-line therapy, which explains Merck's support of the many combination trials that are ongoing at present.

.

Expand

Thanks

VLA Price at posting: 76.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

There are more pages in this discussion • 55 more messages in this thread...

First 9 Last

Add VLA (ASX) to my watchlist